Omni Bio Pharmaceutical, Inc. announced that it has received a notice of allowance from the Canadian Patent Office for the use of AAT in reducing the risk of a non-organ transplant rejection, reducing the risk of developing graft versus host disease (GvHD) and for treating GvHD in patients who have received a cornea, bone marrow, stem cell or pancreatic islet cell transplant. Patent applications covering similar claims are under review in the U.S. and Europe. The claims granted by this notice of allowance include a composition comprising AAT or a carboxyterminal peptide corresponding to AAT or combination thereof, and a carrier or diluent, for use in: reducing a non-organ transplant rejection or for reducing the risk of a non-organ transplant rejection, wherein the non-organ transplant is selected from the group consisting of cornea, bone marrow, stem cell, pancreatic islet, and a combination thereof; and reducing the risk of developing symptoms of GvHD, or for treating GvHD in a subject that has received a non-organ transplant, wherein the non-organ transplant is selected from the group consisting of cornea, bone marrow, stem cell, pancreatic islet, and a combination thereof.